|Videos|January 30, 2023
Overview of Triple Class Refractory Multiple Myeloma
Author(s)Joshua Richter, MD, Srdan Verstovsek, MD, PhD
Dr Joshua Richter explains triple class refractory myeloma and the need for more data on treatment options.
Advertisement
Episodes in this series
Advertisement
Related to this article
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5